Ruxolitinib Can Cause Hepatic Impairment But Not Classic DILI
Ruxolitinib is associated with hepatic impairment requiring dose adjustments in patients with pre-existing liver disease, but it does not typically cause drug-induced liver injury (DILI) in the classic sense. The evidence shows that ruxolitinib requires monitoring and dose modifications for hepatic dysfunction, but liver injury is not a characteristic adverse event of this medication.
Evidence from Guidelines and Drug Labels
The NCCN guidelines for myeloproliferative neoplasms explicitly state that dose reduction is recommended for patients with any degree of hepatic impairment when platelet counts are between 50-150 × 10⁹/L 1. This indicates ruxolitinib requires adjustment in liver disease but does not identify it as a hepatotoxic agent.
The FDA drug label for ruxolitinib does not list hepatotoxicity or DILI among its adverse events 2. The primary adverse events documented are:
- Hematologic toxicities (anemia, thrombocytopenia, neutropenia)
- Infections (including herpes zoster reactivation)
- Lipid elevations
- Hepatitis B reactivation in patients with chronic HBV 1
Hepatitis B Reactivation vs. DILI
An important distinction: The NCCN guidelines note that increases in HBV-DNA titer with or without associated elevations in ALT/AST have been reported in patients with chronic HBV infections treated with ruxolitinib 1. This represents viral reactivation causing liver injury, not direct drug-induced hepatotoxicity.
Clinical Trial Safety Data
In the REACH1 trial for steroid-refractory acute GVHD, the most commonly reported adverse events were hematologic (anemia, thrombocytopenia, neutropenia) followed by infections and edema 3. Hepatotoxicity was not identified as a significant adverse event in these trials.
Recent Research Findings
A 2025 analysis of the Japanese Adverse Drug Event Report database found that ruxolitinib was associated with anemia (adjusted reporting odds ratio 18.49), myelosuppression, infections, and cardiac events 4. Notably, "hepatic function abnormal" had a modest association (aOR 1.60,95% CI: 1.15-2.23), which is substantially lower than the associations seen with hematologic toxicities.
Interestingly, preclinical research suggests ruxolitinib may actually be hepatoprotective in certain contexts. A 2026 study demonstrated that ruxolitinib attenuated diethylnitrosamine-induced liver injury in mice by suppressing inflammatory pathways 5.
Clinical Monitoring Recommendations
While ruxolitinib does not cause classic DILI, monitoring is still warranted:
- Baseline assessment: Document hepatic function before initiating therapy
- Dose adjustments: Reduce dose in patients with pre-existing hepatic impairment and platelet counts 50-150 × 10⁹/L 1
- HBV screening: Test for chronic HBV infection before starting ruxolitinib, as viral reactivation can cause liver injury 1
- Lipid monitoring: Assess lipid parameters 8-12 weeks after initiation, as lipid elevations are common 1
Key Clinical Pitfall
Do not confuse hepatitis B reactivation with DILI. If liver enzymes elevate in a patient on ruxolitinib, evaluate for HBV reactivation, disease progression (especially in myelofibrosis patients), or other causes before attributing it to direct drug hepatotoxicity. The evidence does not support ruxolitinib as a typical DILI-causing agent.